GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Net Change in Cash

Betta Pharmaceuticals Co (SZSE:300558) Net Change in Cash : ¥-31 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Betta Pharmaceuticals Co's Net Change in Cash for the three months ended in Mar. 2024 was ¥-198 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-31 Mil.

Betta Pharmaceuticals Co Net Change in Cash Historical Data

The historical data trend for Betta Pharmaceuticals Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Net Change in Cash Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.33 824.65 -553.96 -60.70 20.71

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.31 78.14 31.20 57.69 -197.98

Betta Pharmaceuticals Co Net Change in Cash Calculation

Betta Pharmaceuticals Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=914.228+-1505.453+608.193+3.744
=21

Betta Pharmaceuticals Co's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=247.236+-491.145+47.575+-1.641
=-198

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Betta Pharmaceuticals Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Net Change in Cash
Comparable Companies
SHSE:600521 SHSE:600566 SHSE:600129 SHSE:600518 SHSE:688276 SHSE:600380 SZSE:002262 SHSE:600535 SHSE:600867 SHSE:603456 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Website
http://www.bettapharma.com
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines